Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
AMRN
HOLDAmarin Corporation plc · Healthcare · Ireland · $284M · Avg Vol: $1M/d
COMPANY DESCRIPTION
Amarin Corporation plc is an Irish pharmaceutical company dedicated to the development and commercialization of therapeutics for cardiovascular health, centered on its flagship product, Vascepa. The company's market position is defined by its pioneering work in purified omega-3 prescription drugs, though it currently faces intense generic competition in the United States. Amarin is actively transitioning its growth strategy toward European and international markets where it retains stronger patent protection and regulatory exclusivity.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 369.2M | 306.9M | 228.6M | 213.6M | -16.7% | 216.8M | 177.8M | 158.8M | -13.8% |
| EPS | -100.27 | -58.49 | -78.51 | -35.73 | — | — | — | — | — |
| Shares | 21.0M | 21.0M | 21.0M | 21.0M | 0.0% | 21.0M | — | — | — |
| Debt | 10.0M | 8.7M | 7.7M | 6.1M | -15.3% | 7.7M | — | — | — |
| Equity | 595.3M | 552.1M | 486.2M | 459.3M | -8.3% | — | — | — | — |
| Op CF | -180.1M | 6.9M | -31.0M | 6.7M | -1.1% | 25.6M | — | — | — |
| Inv CF | 175.3M | -25.5M | -46.0M | 8.8M | — | — | — | — | — |
| Fin CF | -0.4M | 0.2M | -1.4M | -2.0M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of AMRN are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| AMRN | Amarin Corporation plc(you) | $284M | 45 | HOLD |
| COPN.SW | Cosmo N.V. | $1.4B | 19 | STRONG SELL |
| PRTA | Prothena Corporation plc | $458M | 28 | SELL |
| PRGO | Perrigo Company plc | $1.4B | 51 | HOLD |
| GHRS | GH Research PLC | $1.9B | 34 | SELL |
| UPR.L | Uniphar plc | $1.4B | 67 | BUY |
| 0RGI.L | Cosmo Pharmaceuticals N.V. | $1.8B | 17 | STRONG SELL |
| ICLR | ICON Public Limited Company | $12.8B | 57 | HOLD |
| ALKS | Alkermes plc | $8.8B | 78 | BUY |
| JAZZ | Jazz Pharmaceuticals plc | $15.9B | 88 | STRONG BUY |
Peer medians: ROE 1.8% · P/E 23.4x · Gross margin 48.5%